Monoclonal Mouse anti‑Human SIRPB1 / CD172b Antibody (clone OTI3G8, Carrier‑free, aa30‑398, WB) LS‑C792835
Monoclonal Mouse anti‑Human SIRPB1 / CD172b Antibody (clone OTI3G8, Carrier‑free, aa30‑398, WB) LS‑C792835
Antibody:
SIRPB1 / CD172b Mouse anti-Human Monoclonal (aa30-398) (Carrier-free) (OTI3G8) Antibody
Format:
Unconjugated, Carrier-free
Overview
Antibody:
SIRPB1 / CD172b Mouse anti-Human Monoclonal (aa30-398) (Carrier-free) (OTI3G8) Antibody
Format:
Unconjugated, Carrier-free
Specifications
Description
CD172b antibody LS-C792835 is an unconjugated mouse monoclonal antibody to human CD172b (SIRPB1) (aa30-398). Validated for WB.
Target
Human SIRPB1 / CD172b
Synonyms
SIRPB1 | CD172b | SIRP-BETA-1 | CD172b antigen | SIRP-beta-1 isoform 3
Reactivity
Human
(tested or 100% immunogen sequence identity)
Clonality
IgG1
Monoclonal
Conjugations
Unconjugated
Purification
Affinity chromatography
Modifications
Carrier-free.
Also available
Unmodified.
Immunogen
Human recombinant protein fragment corresponding to amino acids 30-398 of human SIRPB1 (NP_006056) produced in E.coli.
Usage
Applications should be user optimized.
Presentation
PBS, pH 7.3, 8% Trehalose
Reconstitution
Reconstitute with PBS pH 7.3. To use this carrier-free antibody for conjugation experiment, we strongly recommend you to perform another round of desalting process.
Storage
Store at -20°C. Avoid freeze-thaw cycles.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
Featured Products
Species:
Mouse
Applications:
Western blot
Species:
Human, Mouse
Applications:
IHC, IHC - Paraffin, Immunofluorescence, Western blot, ELISA
Source:
E. coli
Tag:
His-T7
Source:
E. coli
Tag:
His, N-Terminal
Reactivity:
Human
Range:
0.16-10 ng/ml
Reactivity:
Human
Range:
6.14-1500 pg/ml
Request SDS/MSDS
To request an SDS/MSDS form for this product, please contact our Technical Support department at:
Technical.Support@LSBio.com
Requested From: United States
Date Requested: 4/29/2024